A DT I-NP O
limitation NN I-NP O
of IN I-PP O
the DT I-NP O
pharmacyte NN I-NP I-KP
approach NN I-NP I-KP
is VBZ I-VP O
the DT I-NP O
nature NN I-NP O
of IN I-PP O
the DT I-NP O
intervention: JJ I-NP O
ACT NNP I-NP I-KP
can MD I-VP O
only RB I-VP O
be VB I-VP O
loaded VBN I-VP O
once RB O O
with IN I-PP O
a DT I-NP O
cargo NN I-NP O
of IN I-PP O
adjuvant JJ I-NP I-KP
drug NN I-NP I-KP
prior RB O O
to TO I-VP O
transfer, VB I-VP O
and CC I-VP O
the DT I-NP O
duration NN I-NP O
of IN I-PP O
stimulation NN I-NP I-KP
is VBZ I-VP O
inherently RB I-VP O
limited VBN I-VP O
by IN I-PP O
expansion NN I-NP I-KP
of IN I-PP I-KP
the DT I-NP I-KP
cell NN I-NP I-KP
population NN I-NP I-KP
in IN I-PP I-KP
vivo, JJ I-NP I-KP
since IN I-PP O
particles NNS I-NP I-KP
are VBP I-VP O
diluted VBN I-VP O
with IN I-PP O
each DT I-NP O
cell NN I-NP I-KP
division. NN I-NP I-KP

We PRP I-NP O
hypothesized VBD I-VP O
that IN I-PP O
a DT I-NP O
strategy NN I-NP O
to TO I-VP O
target VB I-VP O
supporting VBG I-VP I-KP
drugs NNS I-NP I-KP
to TO I-VP O
with IN I-PP O
nanoparticle JJ I-NP I-KP
drug NN I-NP I-KP
carriers NNS I-NP I-KP
directly RB O O
in IN I-PP O
vivo NN I-NP O
would MD I-VP O
enable VB I-VP O
transferred JJ I-NP I-KP
lymphocytes NNS I-NP I-KP
to TO I-VP O
be VB I-VP O
repeatedly RB O O
stimulated VBN I-VP O
with IN I-PP O
supporting VBG I-VP I-KP
adjuvant JJ I-NP I-KP
drugs, NN I-NP I-KP
and CC O O
thereby RB O O
provide VB I-VP O
continuous JJ I-NP O
supporting VBG I-NP O
signals NNS I-NP O
over IN I-PP O
the DT I-NP O
prolonged JJ I-NP O
durations NNS I-NP O
that WDT B-NP O
might MD I-VP O
be VB I-VP O
necessary JJ I-NP O
for IN I-PP O
elimination NN I-NP I-KP
of IN I-PP I-KP
large JJ I-NP I-KP
tumor NN I-NP I-KP
burdens. NN I-NP I-KP

Such JJ I-NP O
of IN I-PP I-KP
with IN I-PP I-KP
supporting VBG I-VP I-KP
drugs NNS I-NP I-KP
could MD I-VP O
be VB I-VP O
achieved VBN I-VP O
by IN I-PP O
repeated JJ I-NP O
administration NN I-NP I-KP
of IN I-PP I-KP
targeted JJ I-NP I-KP
particles, NN I-NP I-KP
allowing VBG I-VP O
to TO I-VP O
be VB I-VP O
restimulated VBN I-VP O
multiple JJ I-NP O
times NNS I-NP O
directly RB O O
in IN I-PP O
vivo, NN I-NP O
while IN I-PP O
the DT I-NP O
use NN I-NP O
of IN I-PP O
internalizing VBG I-VP I-KP
targeting VBG I-VP I-KP
ligands NNS I-NP I-KP
would MD I-VP O
minimize VB I-VP O
the DT I-NP O
likelihood NN I-NP O
of IN I-PP O
immune JJ I-NP O
responses NNS I-NP O
against IN I-PP O
the DT I-NP O
nanoparticle NN I-NP I-KP
carrier. NN I-NP I-KP

To TO I-VP O
our PRP$ I-NP O
knowledge, NNS I-NP O
only RB O O
two CD I-NP O
prior JJ I-NP O
studies NNS I-NP O
have VBP I-VP O
attempted VBN I-VP O
to TO I-VP O
target VB I-VP O
nanoparticles NNS I-NP I-KP
to TO I-VP O
in IN I-PP O
vivo NN I-NP O
[17,18]. NN I-NP O

In IN I-PP O
both DT I-NP O
of IN I-PP O
these DT I-NP O
studies, NNS I-NP O
particles NNS I-NP O
were VBD I-VP O
targeted VBN I-VP O
to TO I-VP O
via IN I-PP O
ligands NNS I-NP I-KP
that WDT B-NP O
bind VBP I-VP O
to TO I-VP O
specific JJ I-NP O
receptors. NN I-NP I-KP

However, NNP I-NP O
nanoparticles NNS I-NP I-KP
have VBP I-VP O
recently RB I-VP O
been VBN I-VP O
shown VBN I-VP O
to TO I-VP O
deliver VB I-VP O
an DT I-NP O
anergizing/tolerizing VBG I-NP O
signal NN I-NP O
to TO I-VP O
[18,19] NNP I-NP O
â€” NNP I-NP O
which WDT B-NP O
is VBZ I-VP O
ideal JJ I-NP O
for IN I-PP O
treating VBG I-VP I-KP
graft NN I-NP I-KP
rejection NN I-NP I-KP
or CC O I-KP
autoimmunity, NN I-NP I-KP
but CC O O
runs VBZ I-VP O
counter NN I-NP O
to TO I-VP O
the DT I-NP O
goals NNS I-NP O
of IN I-PP O
cancer NN I-NP I-KP
immunotherapy. NN I-NP I-KP

